ducovest

FINU:ARCA-ProShares UltraPro Financial Select Sector

ETF | Drug Manufacturers | NYSE Arca

Last Closing

USD 74.25

Change

+1.06 (+1.45)%

Market Cap

USD 0.01B

Volume

1.90K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P Financial Select Sector Index. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as three times (3x) the daily return of the index. The index is one of eleven (11) of the S&P Select Sector Indices, each designed to measure the performance of a sector of the S&P 500. The fund is non-diversified.

Company Website : www.proshares.com

Currency: USD

Country : USA

Inception Date: 10/07/2012

Primary Benchmark: S&P Financial Select Sector TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 2.33%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Symbol Company Name Allocation
JPM JPMorgan Chase & Co 10.74 %
BAC Bank of America Corp 6.80 %
WFC Wells Fargo & Company 4.64 %
C Citigroup Inc 4.09 %
Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-08-21 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SCYB Schwab Strategic Trust 0.00 %

-0.32 (-0.63%)

 N/A

ETFs Containing FINU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.47% 76% C+ 88% B+
Dividend Return 0.95% 79% B- 26% F
Total Return 32.42% 79% B- 87% B+
Trailing 12 Months  
Capital Gain -26.83% 8% B- 18% F
Dividend Return 0.81% 26% F 12% F
Total Return -26.02% 11% F 17% F
Trailing 5 Years  
Capital Gain 106.54% 88% B+ 92% A
Dividend Return 3.85% 57% F 13% F
Total Return 110.39% 88% B+ 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 29.46% 100% F 96% N/A
Dividend Return 29.77% 100% F 96% N/A
Total Return 0.31% 38% F 8% B-
Risk Return Profile  
Volatility (Standard Deviation) 56.80% 3% F 5% F
Risk Adjusted Return 52.41% 66% D+ 64% D
Market Capitalization 0.01B 55% F 30% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.